Note: this report is one of two complaints that pertain to the same event and same patient ( mfr.Report #3005099803-2023-04471).It was reported to boston scientific that two advanix biliary stents were successfully placed as stent exchange during an endoscopic retrograde cholangiopancreatography (ercp) procedure in the common bile duct, performed on (b)(6) 2023.From (b)(6) 2023, to (b)(6) 2023, at an outside hospital (osh), the patient experienced acute right upper quadrant (ruq) pain, emesis (vomiting), chills and fever of 100.7 degrees, concerning for cholangitis.The patient was hospitalized and was given levofloxacin, metronidazole, flagyl, dapto, and tylenol as a treatment for cholangitis, fever, and pain; and was also administered with intravenous lactated ringer's (lr) solution for hydration.From april 05 to april 08, 2023, it was reported that the cholangitis was growing and was vancomycin-resistant enterococci complicated by sepsis, and post ercp pancreatitis with hepatic abscess due to the procedure performed on (b)(6) 2023.From (b)(6) 2023 to (b)(6) 2023, the patient experienced abdominal pain in the setting of transaminitis with obstruction.The patient was discharged with ceftriaxone and metronidazole as discharged medication.The fever seemed to be better at the time the patient was discharged.On (b)(6) 2023, another procedure was performed to remove the implanted stents (the subject of this report 3005099803-2023-04471), and a wallflex biliary stent was placed to successfully complete the procedure.The patient was reported to have pancreatic cancer and pain was ongoing.In the physician's assessment, there was a chance that the patient's adverse event was due to the stent change and the cholangitis was concerning for sepsis.
|